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Packer1 says that the one who submits a research for public good
should be ready to receive a request for data sharing for
examination and re-analysis and that tax payers assume that a
national agency is checking such data and analysis. Here we
discuss Cochrane’s practice on data sharing.
Open science, as endorsed by the G7,2 includes sharing data,
computer code, and materials. It is essential for reproducibility,
collaboration, and innovation. We support the work of Cochrane,
but are concerned that Cochrane is not sharing all its reviews’
data. These data should be fully accessible for reuse by third
parties.
Cochrane, a non-profit private company3 and registered charity,
produces and maintains systematic reviews in health and social
care. Its work is undertaken by a global network of thousands
of people,4 and its support largely comes from public funding.5
Most people producing Cochrane reviews are volunteers not
specifically funded for this work,6 7 and Cochrane encourages
“crowdsourcing” of work.8-10
Cochrane editorial bases help volunteers obtain study reports
and manually extract the wealth of data needed to generate
systematic reviews.11-13 Cochrane teams use RevMan software14
to produce files in standard format (XML), storing information
on the studies, their methods, and results for publication in the
Cochrane Library.
Benefits of sharing extracted data from trials and systematic
reviews are well known, as are the costs of not sharing.13 15-17
Sharing maximises transparency, reliability of data extraction,
and syntheses. It improves access to data—saving time and
money—and opens new avenues of inquiry.18 Sharing is
associated with increased citations,19 more publications,20 and
reuse for new purposes.16
Structured data from Cochrane should be fully accessible for
download, reuse, and review (box 1). Currently, they are not.
Although Cochrane supports transparency initiatives such as
AllTrials21 and is explicit about this in its policy,22 it has no
similar clear principles on opening full access to the data in
Cochrane reviews. Cochrane does provide access to results data
from reviews but, crucially, these cannot be readily reused, and
the available information is an incomplete set of the data
generating these reviews, comes in a technically problematic
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format, and can only be viewed by those with access to the full
content of the Cochrane Library.23-25
Box 1: Structured data and associated metadata
Reference data
All data in the Cochrane Central Register of Controlled Trials (CENTRAL)
excluding copyrighted abstracts (so creating OPEN CENTRAL)
All data in the Cochrane Register of Studies (CRS) excluding copyrighted
abstracts (so creating OPEN CRS)
Links to “parent” study
Links to “parent” reviews
Study data
Links to “child” references
Links to “parent” reviews
Characteristics of studies
Methods, participants, interventions, outcomes
Qualitative data on risk of bias
Quantitative data on outcomes
Qualitative and quantitative derived data
Meta-analysis results, grading of quality of outcomes
Small amounts of Cochrane data have been released with
bespoke arrangements for specific individuals. This sharing is
welcome, but organisational culture, policy, and process
regarding data release are lacking; there is no appeals process.
For example, OpenTrials aggregates all accessible documents
on all trials in an open database and makes it free for public
reuse.26 27 Thus far, OpenTrials has been unable to persuade
Cochrane to share data for reuse. The Trip Database28 is a
searchable library of evidence that asked if it could re-present
structured data from Cochrane and also encountered barriers to
access.29 Open sharing could foster collaborative ecosystems of
digital innovation going beyond academic publications, with
outputs that might include live, interactive presentations of
summaries and results of trials produced by teams around the
world, interactive decision support tools, and many more.
Cochrane’s non-release of data is unlikely to reflect the
preferences of funders, publishers, the thousands of Cochrane
volunteers, participants in trials, or patients. When asked, 83%
of the members of the Cochrane Individual Participant Data
Meta-analysis Methods Group supported sharing systematic
review data through a central repository (recognising that these
data might require some form of moderated access).30 Many
funders now require that data arising from their grants are
shared.31-34 Cochrane volunteer authors give tacit consent for
use of their work in reviews but may not be aware of the
restrictions placed on access to the data they worked so hard to
prepare.25 This is morally and ethically questionable, potentially
eroding public trust.16 35
This issue of open science is now pressing, after recent moves
by Cochrane to create more information and become a hub for
systematic review data. This has the potential to improve
evidence and patient care, but although the Cochrane Linked
Data Project aims to share reusable data in some form,36 37 there
is not yet any information on how or when this will happen.38 39
Furthermore, Cochrane is working towards “living” systematic
reviews, with updates from data in real time.40 This is important
work, but progress is slow. Opening up this work with shared
data resources and in collaboration with the open source
software community—where all can contribute—would
accelerate progress and best reflect the culture of collaboration
in science.
Open data offers a transformative, collaborative future for the
systematic review community. Cochrane has enabled a vast
workforce to painstakingly extract information for great benefit.
It could act as a hub, harmonising data collected across groups
and sharing these widely, reflecting the collective funding and
volunteer workforce that produces them. This could include
converting the morass of free text trial reports into machine
readable curated data, in archived, citable, accessible,
interoperable and reusable formats, as set out in the FAIR
principles.41 42 Cochrane could show leadership in supporting
innovation and open science for clinical trials with full credit
to all data extractors before43 and after review publication44 and,
in this way, harness the greatest broadest impact. This reflects
the exciting current move towards better use of data to produce
digital tools of direct value to clinicians, rather than academic
publications alone.
We have raised these issues with Cochrane and understand that
the organisation is considering whether to start reviewing its
approach to sharing data (D Tovey, personal communication,
2017). We hope that our setting out the benefits of open data is
a helpful contribution to open that discussion.
We appreciate that Cochrane must focus on making itself
sustainable and that open data sharing may be commercially
sensitive.45 But making Cochrane a champion for openness,
transparency, and sharing can only be beneficial for the
organisation’s reputation—and finances. We encourage
Cochrane leadership to create a policy that allows open data
sharing and to make explicit any concerns they have on open
data sharing so that these can be resolved.
Key messages
Cochrane could lead and set standards for open data sharing from
systematic reviews
Availability of data from Cochrane reviews would give opportunities for
collaboration, innovation, scientific replication, novel research, and clinical
decision making
It would also reduce the considerable waste of the current duplication of
effort in systematic reviewing
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